The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry
Open Access
- 14 October 2021
- Vol. 9 (4), 153
- https://doi.org/10.3390/economies9040153
Abstract
The significance of the pharmaceutical and commercial sectors in the national economy has noticeably intensified, as a result of the COVID-19 pandemic. The main objective of this study was to gain a better insight into the main management characteristics of the actors in the sector. It was assumed that more efficient management of financial investments (acquisitions, loans) caused higher risk financial investment decisions in the pharmaceutical industry in order to place companies in a better position in view of equity investors, illustrated best as the profitability of equity (ROE). This paper examined one possible means of covering the extremely high indirect costs (R&D, marketing) of pharmaceutical companies, also justified by the restructuring of the industry and the effect of investments in long term financial instruments on the ROE of the same business entities. Built on the EMIS database, the analysis only used the indicators of those companies operating in the pharmaceutical industry in Visegrad countries for 2019. The authors sought to draw conclusions about possible management characteristics of the entire pharmaceutical sector of these countries using cluster analysis and linear regression. The initial assumption, or main hypothesis of the study, was that in one of the countries studied or for those businesses operating above a certain revenue category, the impact of a company’s risk-taking (which can also be expressed in terms of asset-based financial income) on profitability, may appear or intensify. The performed studies did not show a strong correlation between the explanatory and profit variables either at the national level or at the level of groups formed by regional market position. In other words, the extremely high level of indirect costs were mostly covered by sales of successful cash products, and companies not indebted to suppliers undertook significant risks in the field of financial investments, thereby offsetting the positive impact of the latter on earnings.Keywords
Funding Information
- European Social Fund (EFOP-3.6.3-VEKOP-16-2017-00007)
This publication has 22 references indexed in Scilit:
- IAS 39 reclassification choice and analyst earnings forecast propertiesJournal of Accounting and Public Policy, 2013
- Why is pharma a special industry?Published by Elsevier BV ,2013
- Drug discovery in pharmaceutical industry: productivity challenges and trendsDrug Discovery Today, 2012
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Innovation Policy Challenges in Transition Countries: Foreign Business R&D in the Czech Republic and HungaryTransition Studies Review, 2009
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Strategic trends in the drug industryDrug Discovery Today, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- The Link Between Gross Profitability And Pharmaceutical R&D SpendingHealth Affairs, 2001
- Finance Theory and Financial StrategyInforms Journal on Applied Analytics, 1984